[go: up one dir, main page]

WO2008120736A1 - Transpulmonary liposome for controlling drug arrival - Google Patents

Transpulmonary liposome for controlling drug arrival Download PDF

Info

Publication number
WO2008120736A1
WO2008120736A1 PCT/JP2008/056156 JP2008056156W WO2008120736A1 WO 2008120736 A1 WO2008120736 A1 WO 2008120736A1 JP 2008056156 W JP2008056156 W JP 2008056156W WO 2008120736 A1 WO2008120736 A1 WO 2008120736A1
Authority
WO
WIPO (PCT)
Prior art keywords
liposome
controlling drug
arrival
transpulmonary
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056156
Other languages
French (fr)
Japanese (ja)
Inventor
Hirofumi Takeuchi
Koji Nakano
Hidekazu Toyobuku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009010479A priority Critical patent/MX2009010479A/en
Priority to AU2008233656A priority patent/AU2008233656B2/en
Priority to JP2009507528A priority patent/JP5191478B2/en
Priority to NZ579881A priority patent/NZ579881A/en
Priority to US12/593,827 priority patent/US8658204B2/en
Priority to CA2682376A priority patent/CA2682376C/en
Priority to ES08739274.2T priority patent/ES2618457T3/en
Priority to RU2009140058/15A priority patent/RU2493874C2/en
Priority to EP08739274.2A priority patent/EP2133097B1/en
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to BRPI0809852-2A priority patent/BRPI0809852A2/en
Priority to KR1020147029191A priority patent/KR20140136047A/en
Publication of WO2008120736A1 publication Critical patent/WO2008120736A1/en
Priority to IL201172A priority patent/IL201172A0/en
Priority to ZA2009/06742A priority patent/ZA200906742B/en
Anticipated expiration legal-status Critical
Priority to US14/108,826 priority patent/US9750694B2/en
Priority to PH12014502430A priority patent/PH12014502430A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

It is intended to provide a liposome which is excellent in the ability to control the intrapulmonary arrival of a drug or a gene and is suitable for transpulmonary administration. By modifying the surface of a liposome by using a terminal-hydrophobic polyvinyl alcohol and/or chitosan, the retention on the pulmonary tissue surface or the migration into the pulmonary tissue of a gene or a drug encapsulated in the liposome can be appropriately controlled, which makes it possible to control the behaviors thereof in vivo.
PCT/JP2008/056156 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival Ceased WO2008120736A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP08739274.2A EP2133097B1 (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
JP2009507528A JP5191478B2 (en) 2007-03-30 2008-03-28 Transpulmonary administration liposome for drug delivery control
BRPI0809852-2A BRPI0809852A2 (en) 2007-03-30 2008-03-28 TRANSPULMONARY LIPOSOMA TO CONTROL PHARMACEUTICAL ARRIVAL
US12/593,827 US8658204B2 (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
CA2682376A CA2682376C (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
ES08739274.2T ES2618457T3 (en) 2007-03-30 2008-03-28 Transpulmonary liposome to control the arrival of the drug
RU2009140058/15A RU2493874C2 (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug delivery
MX2009010479A MX2009010479A (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival.
NZ579881A NZ579881A (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
AU2008233656A AU2008233656B2 (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
KR1020147029191A KR20140136047A (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
IL201172A IL201172A0 (en) 2007-03-30 2009-09-24 Transpulmonary liposome for controlling drug arrival
ZA2009/06742A ZA200906742B (en) 2007-03-30 2009-09-28 Transpulmonary liposome for controlling drug arrival
US14/108,826 US9750694B2 (en) 2007-03-30 2013-12-17 Transpulmonary liposome for controlling drug arrival
PH12014502430A PH12014502430A1 (en) 2007-03-30 2014-10-30 Transpulmonary liposome for controlling drug arrival

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-090874 2007-03-30
JP2007090874 2007-03-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/593,827 A-371-Of-International US8658204B2 (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival
US14/108,826 Continuation US9750694B2 (en) 2007-03-30 2013-12-17 Transpulmonary liposome for controlling drug arrival

Publications (1)

Publication Number Publication Date
WO2008120736A1 true WO2008120736A1 (en) 2008-10-09

Family

ID=39808316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056156 Ceased WO2008120736A1 (en) 2007-03-30 2008-03-28 Transpulmonary liposome for controlling drug arrival

Country Status (20)

Country Link
US (2) US8658204B2 (en)
EP (2) EP2133097B1 (en)
JP (2) JP5191478B2 (en)
KR (2) KR101476167B1 (en)
CN (2) CN103356482A (en)
AR (1) AR065865A1 (en)
AU (2) AU2008233656B2 (en)
BR (1) BRPI0809852A2 (en)
CA (2) CA2885621C (en)
CO (1) CO6260108A2 (en)
ES (2) ES2643938T3 (en)
IL (1) IL201172A0 (en)
MX (1) MX2009010479A (en)
NZ (1) NZ579881A (en)
PH (1) PH12014502430A1 (en)
RU (1) RU2493874C2 (en)
TW (1) TW200902085A (en)
UA (1) UA100375C2 (en)
WO (1) WO2008120736A1 (en)
ZA (1) ZA200906742B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011246464A (en) * 2010-04-28 2011-12-08 Wakamoto Pharmaceutical Co Ltd Polymer coating liposome for arriving at posterior eye segment sealed with diclofenac sodium
JP2012513460A (en) * 2008-12-26 2012-06-14 サムヤン コーポレイション Anionic drug-containing pharmaceutical composition and method for producing the same
JP2016511255A (en) * 2013-02-28 2016-04-14 チョン クン ダン ファーマシューティカル コーポレーション Composition for gene transfer comprising chitosan and liquid crystal forming substance
WO2017046416A1 (en) 2015-09-18 2017-03-23 Technische Universität München LIGANDS FOR INTEGRIN AVß6, SYNTHESIS AND USES THEREOF
WO2018167295A1 (en) 2017-03-17 2018-09-20 Technische Universität München LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN107002081A (en) 2014-10-06 2017-08-01 埃克西奎雷股份有限公司 Anti- TNF compounds
CN104922068B (en) * 2015-05-22 2017-10-13 江苏凯基生物技术股份有限公司 A kind of Decoy nucleic acid cationics liposome vectors and preparation method thereof
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US20200297867A1 (en) * 2016-02-01 2020-09-24 Exicure, Inc. Surface functionalization of liposomes and liposomal spherical nucleic acids (snas)
KR102617833B1 (en) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 Liposomal spherical nucleic acid (SNA) construct presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
TWI754659B (en) * 2016-08-08 2022-02-11 台灣微脂體股份有限公司 Delivery vehicle, method and kit for preparing a liposomal composition containing mild acidic agent
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
TWI734987B (en) * 2019-05-23 2021-08-01 國立陽明交通大學 Monosaccharide-tagged nano-liposome drug delivery system, the manufacture and use for drug targeting delivery thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528131A (en) * 2000-03-29 2003-09-24 アラダイム コーポレーション Cationic liposome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
RU2130771C1 (en) 1998-06-01 1999-05-27 Автушенко Сергей Сергеевич Method of preparing liposomal preparations
JP2003516926A (en) * 1998-11-18 2003-05-20 ユニバーシティ オブ フロリダ Method for preparing coated drug particles and pharmaceutical formulations thereof
JP2003504321A (en) 1999-07-08 2003-02-04 オーランド・ハン Pulmonary delivery of liposome-encapsulated cannabinoids
US20030096774A1 (en) * 2001-11-21 2003-05-22 Igor Gonda Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
DE10214983A1 (en) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Nebulisable liposomes and their use for pulmonary application of active substances
CA2486622A1 (en) * 2002-05-20 2003-12-04 Research Development Foundation Aerosol drug inhibition of lung metastases
RU2238091C2 (en) * 2002-12-15 2004-10-20 Закрытое акционерное общество "АИП-Наука" Method for treating human tuberculosis
WO2004110493A2 (en) * 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
JP4503953B2 (en) 2003-08-11 2010-07-14 テルモ株式会社 Manufacturing method of prefilled syringe
JP4669665B2 (en) 2004-04-12 2011-04-13 正彦 阿部 Polycation-modified liposome having no cytotoxicity and method for producing the same
CN100356919C (en) * 2004-05-31 2007-12-26 上海医药工业研究院 Hydroxycamptothecin liposome and its preparation
CN101018560A (en) * 2004-09-15 2007-08-15 大塚制药株式会社 Permucosal composition and method of improving permucosal absorption

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528131A (en) * 2000-03-29 2003-09-24 アラダイム コーポレーション Cationic liposome

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
KAWASHIMA Y.: "Nan'yokaiseki Yakubutsu ya Peptide-sei Yakubutsu o Taisho ni shita Keinenmaku (Keihai ya Keiko) Toyoyo Shinki Nano Ryushi Carrier System ni yoru DDS (Yakubutsu Sotatsu System) no Saiteki Sekkeiho no Kaihatsu to Taikeika", RESEARCH REPORTS OF UEHARA MEMORIAL FOUNDATION, vol. 17, 2003, pages 1 - 3, XP008142120 *
SATO T. ET AL.: "In vitro gene delivery mediated by chitosan. Effect of pH, serum, and molecular mass of chitosan on the transfection efficiency", BIOMATERIALS, vol. 22, no. 15, 2001, pages 2075 - 2080, XP004298300 *
See also references of EP2133097A4
TAKEUCHI H ET AL.: "Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs", INT J PHARM., vol. 303, no. 1-2, 13 October 2005 (2005-10-13), pages 160 - 170, XP005080652, DOI: doi:10.1016/j.ijpharm.2005.06.028
TAKEUCHI H ET AL.: "Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats", J CONTROL RELEASE., vol. 75, no. 1-2, 10 July 2001 (2001-07-10), pages 83 - 91, XP004254405, DOI: doi:10.1016/S0168-3659(01)00368-6
TAKEUCHI H. ET AL.: "Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs", INT. J. PHARM., vol. 303, no. 1-2, 13 October 2005 (2005-10-13), pages 160 - 17, XP005080652, DOI: doi:10.1016/j.ijpharm.2005.06.028
TAKEUCHI H. ET AL.: "Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes", PHARM. RES., vol. 13, no. 6, 1996, pages 896 - 901, XP002055070, DOI: doi:10.1023/A:1016009313548
TAKEUCHI H. ET AL.: "Mucoadhesive liposomes coated with chitosan or carbopol for oral administration of peptide drugs", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, vol. 26, no. 1, 1999, pages 988 - 989, XP002964493
TAKEUCHI H. ET AL.: "Mucoadhesive nanoparticulate systems for peptide drug delivery", ADVANCED DRUG DELIVERY REVIEWS, vol. 47, no. 1, 2001, pages 39 - 54, XP008117909, DOI: doi:10.1016/S0169-409X(00)00120-4
TAKEUCHI H. ET AL.: "Mucoadhesive nanoparticulate systems for peptide drug delivery", ADVANCED DRUG DELIVERY REVIEWS, vol. 47, no. 1, 23 March 2001 (2001-03-23), pages 39 - 54, XP008117909 *
TAKEUCHI H. ET AL.: "Physical stability of size controlled small unilamellar liposomes coated with a modified polyvinyl alcohol", J. PHARM., vol. 164, no. 1-2, 1998, pages 103 - 111, XP002501522, DOI: doi:10.1016/S0378-5173(97)00404-3
TAKEUCHI H. ET AL.: "Physical stability of size controlled small unilamellar liposomes coated with a modified polyvinyl alcohol", JOURNAL OF PHARMACEUTICS, vol. 164, no. 1-2, 1998, pages 103 - 111, XP002501522 *
TAKEUCHI H. ET AL.: "Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats", J. CONTROLLED RELEASE, vol. 68, no. 2, 2000, pages 195 - 205, XP004228950, DOI: doi:10.1016/S0168-3659(00)00260-1
TAKEUCHI H. ET AL.: "Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats", JOURNAL OF CONTROLLED RELEASE, vol. 68, no. 2, 10 August 2000 (2000-08-10), pages 195 - 205, XP004228950 *
TAKEUCHI H. ET AL.: "Yakubutsu Carrier to shite no Liposome, Piddo Maikuro Sufea ni Kansuru Seizaigakuteki Kenkyu", HYOMEN, vol. 32, no. 6, 1 June 1994 (1994-06-01), pages 423 - 429, XP008117761 *
YAMAMOTO H.: "Peptide no Keinenmaku Toyo o Mezashita Seibunkaisei Biryushiseizai no Sekkei", 23NUAL PROCEEDINGS OF THE PHARMACEUTICAL UNIVERSITY, vol. 49, 2000, pages 23 - 32, XP008117762 *
YAMAMOTO, H.: "Peptide no Keinenmaku Toyo o Mezashita Seibunkaisei Biryushiseizai no Sekkei", ANNUAL PROC. GIFU PHARM. UNIV., vol. 49, 2000, pages 23 - 32, XP008117762

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513460A (en) * 2008-12-26 2012-06-14 サムヤン コーポレイション Anionic drug-containing pharmaceutical composition and method for producing the same
JP2011246464A (en) * 2010-04-28 2011-12-08 Wakamoto Pharmaceutical Co Ltd Polymer coating liposome for arriving at posterior eye segment sealed with diclofenac sodium
JP2016511255A (en) * 2013-02-28 2016-04-14 チョン クン ダン ファーマシューティカル コーポレーション Composition for gene transfer comprising chitosan and liquid crystal forming substance
US11318215B2 (en) 2013-02-28 2022-05-03 Chong Kun Dang Pharmaceutical Corp. Composition for gene delivery comprising chitosan and liquid crystal formation material
WO2017046416A1 (en) 2015-09-18 2017-03-23 Technische Universität München LIGANDS FOR INTEGRIN AVß6, SYNTHESIS AND USES THEREOF
WO2018167295A1 (en) 2017-03-17 2018-09-20 Technische Universität München LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF

Also Published As

Publication number Publication date
EP2133097A4 (en) 2013-01-16
ES2643938T3 (en) 2017-11-27
CA2682376A1 (en) 2008-10-09
EP2133097B1 (en) 2017-01-25
EP2133097A1 (en) 2009-12-16
CN101646462A (en) 2010-02-10
KR101476167B1 (en) 2014-12-24
RU2009140058A (en) 2011-05-10
US8658204B2 (en) 2014-02-25
US20140105968A1 (en) 2014-04-17
US9750694B2 (en) 2017-09-05
CA2885621C (en) 2016-01-05
MX2009010479A (en) 2009-10-19
TW200902085A (en) 2009-01-16
RU2493874C2 (en) 2013-09-27
UA100375C2 (en) 2012-12-25
ES2618457T3 (en) 2017-06-21
AU2008233656A1 (en) 2008-10-09
BRPI0809852A2 (en) 2014-09-23
CA2885621A1 (en) 2008-10-09
AU2014204483A1 (en) 2014-08-07
JP5674831B2 (en) 2015-02-25
IL201172A0 (en) 2010-05-17
PH12014502430A1 (en) 2015-09-07
KR20140136047A (en) 2014-11-27
AR065865A1 (en) 2009-07-08
CO6260108A2 (en) 2011-03-22
EP2656858A1 (en) 2013-10-30
AU2008233656B2 (en) 2014-05-22
CA2682376C (en) 2015-10-06
EP2656858B1 (en) 2017-08-16
JPWO2008120736A1 (en) 2010-07-15
ZA200906742B (en) 2010-12-29
KR20090128491A (en) 2009-12-15
JP2013100332A (en) 2013-05-23
US20100112043A1 (en) 2010-05-06
NZ579881A (en) 2012-10-26
CN103356482A (en) 2013-10-23
JP5191478B2 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
WO2008120736A1 (en) Transpulmonary liposome for controlling drug arrival
USD638016S1 (en) Game controller
USD667892S1 (en) Game controller
USD621500S1 (en) Medical injector
USD598396S1 (en) Control panel for an elevator
USD667240S1 (en) Ball display apparatus
USD678281S1 (en) Game console
USD691710S1 (en) Medical device inserter
USD646275S1 (en) Game controller with elongated controller element
USD624080S1 (en) Asymmetrical game controller
USD633549S1 (en) Swimming goggles
USD643936S1 (en) Controller for liquid chromatograph analyzer
WO2010140869A3 (en) Complex, multilayer using the same, and device coated with the multilayer
WO2007146426A3 (en) Nanoshells for drug delivery
USD605771S1 (en) Dental control unit
EP2178891B8 (en) Phosphonous acids, salts and esters, methods for the production thereof, and use of same
WO2010021879A3 (en) Use of ultrarapid acting insulin
USD681806S1 (en) Infusion pump for pharmaceutical drugs
WO2006133102A3 (en) Agent delivery system and uses of the same
EP2203213A4 (en) Transseptal cannula, tip, delivery system, and method
WO2011003822A3 (en) Aqueous insulin preparations containing methionine
WO2008101968A8 (en) A method for delivery of a therapeutic substance into the skin
USD644695S1 (en) Control device for electronic games
USD599905S1 (en) Controller for endoscope
WO2009125986A3 (en) Lyophilized dna formulations for enhanced expression of plasmid dna

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010670.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739274

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12009501789

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008233656

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 579881

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 201172

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2009507528

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6197/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2682376

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12593827

Country of ref document: US

Ref document number: MX/A/2009/010479

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PI20094070

Country of ref document: MY

Ref document number: 2009091441

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008739274

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008739274

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008233656

Country of ref document: AU

Date of ref document: 20080328

Kind code of ref document: A

Ref document number: 20097021573

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A200910942

Country of ref document: UA

Ref document number: 2009140058

Country of ref document: RU

Ref document number: 09123134

Country of ref document: CO

ENP Entry into the national phase

Ref document number: PI0809852

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090930